From: D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy
Regimen | Total number of patients (n = 139) | Number of patients who completed the NACT (n = 133)a | Toxicity grade |
---|---|---|---|
EOX3 | 87 | 83 (1 patient received 2 additional cycles) | Tolerated toxicities |
Grade I vomiting (5 patients) | |||
Grade I diarrhea (1 patient) | |||
Grade I vomiting and diarrhea (2 patients) | |||
Grade I skin and hair toxicity (1 patient) | |||
Grade I neutropenia (1 patient) | |||
Grade II vomiting (3 patients) | |||
Grade II diarrhea (1 patient) | |||
Grade II vomiting and diarrhea (1 patient) | |||
Grade III hand-foot syndrome (1 patient) | |||
Grade IV diarrhea (1 patient) | |||
Grade IV thrombocytopenia (2 patients) | |||
Toxicities resulting in alterations in regimen | |||
Grade I diarrhea, and on and off febrile illness (1 patient, resulted in reduced cycles) | |||
Grade III fatigue (1 patient, resulted in reduced cycles) | |||
Grade III diarrhea (1 patient, resulted in reduced cycles) | |||
Grade IV vomiting and diarrhea (1 patient, resulted in reduced cycles) | |||
Grade III vomiting (1 patient, protocol changed to EOF after 1 cycle) | |||
ECF3 | 24 | 23 (1 patient received an additional cycle of docetaxel and oxaliplatin) | Grade I diarrhea (2 patients) |
Grade I vomiting (1 patient) | |||
Grade II vomiting and diarrhea (1 patient) | |||
Grade IV mucositis (2 patients) | |||
Grade IV diarrhea (1 patient) | |||
Grade IV vomiting and diarrhea (1 patient) | |||
Toxicities resulting in alterations in regimen | |||
Grade IV diarrhea (1 patient, resulted in reduced cycles) | |||
EOF3 | 9 | 8 | Grade I vomiting (1 patient) |
Grade I diarrhea (2 patients) | |||
Toxicities resulting in alterations in regimen | |||
Grade IV mucositis (1 patient, resulted in 25% dose reduction and reduced cycles) | |||
Grade III febrile neutropenia (1 patient, resulted in 20% dose reduction) | |||
CAPOX3 | 7 | 7 | Grade 1 nausea, vomiting (2 patients) |
EO3 | 1 | 1 | |
DCF | 6 | 6 (3 patients received 3 cycles each and 1 patient each received 4, 5 and 6 cycles, respectively) | Anemia after 1 cycle and grade 1 diarrhea after 2 cycles (1 patient) |
Grade II febrile neutropenia (1 patient) | |||
Grade III diarrhea (1 patient) | |||
1 patient developed chicken pox while on chemotherapy | |||
ECX3 | 5 | 5 | Toxicities resulting in alterations in regimen |
Grade 1 nausea and vomiting (1 patient, protocol changed to ECF after 1 cycle) |